Abbott leader on the ‘hype’ and ‘reality’ of pulsed field ablation

MedTech Dive March 1, 2024
Susan Kelly

Christopher Piorkowski, chief medical officer for the electrophysiology business, talks about the high expectations for the new atrial fibrillation treatment.

Christopher Piorkowski, chief medical officer of Abbott’s large and fast-growing electrophysiology business, recently visited clinical sites in Australia and across Europe to gather feedback on the first patients enrolled in a pre-market study of the company’s Volt pulsed field ablation (PFA) system.

PFA is a new technique for treating atrial fibrillation (AFib), a heart rhythm disorder that increases a patient’s risk for stroke from a blood clot. The treatment is attracting considerable investment from medtech companies: Medtronic in December became the first device maker to gain Food and Drug Administration approval for a PFA system, and Boston Scientific and Johnson...

Today's Sponsors

Today's Sponsor